<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We sought to determine whether expression of the inducible, calcium-independent isoform of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (iNOS) contributes to the tissue damage produced by focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The middle cerebral artery was occluded in <z:chebi fb="2" ids="5615">halothane</z:chebi>-anesthetized spontaneously hypertensive rats </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-four hours later rats received intraperitoneal injections of the iNOS inhibitor <z:chebi fb="0" ids="40618">aminoguanidine</z:chebi> (100 mg/kg twice per day; n = 10) or of <z:chebi fb="0" ids="40618">aminoguanidine</z:chebi> + <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> (300 mg/kg four times per day; n = 7), <z:chebi fb="0" ids="40618">aminoguanidine</z:chebi> + <z:chebi fb="0" ids="15816">D-arginine</z:chebi> (n = 7), arginine alone (n = 6), or vehicle (n = 9) </plain></SENT>
<SENT sid="3" pm="."><plain>Drugs were administered for 3 consecutive days </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume was determined by image analysis in <z:chebi fb="0" ids="52295">thionin</z:chebi>-stained brain sections 4 days after induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Administration of <z:chebi fb="0" ids="40618">aminoguanidine</z:chebi> reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 33 +/- 4% (P &lt; 0.05 from vehicle; analysis of variance and Tukey's test), a reduction that was antagonized by coadministration of L- but not <z:chebi fb="0" ids="15816">D-arginine</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Administration of <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> alone did not affect <z:mpath ids='MPATH_124'>infarct</z:mpath> size (P &gt; 0.05 vs. vehicle) </plain></SENT>
<SENT sid="7" pm="."><plain>In separate rats (n = 10), <z:chebi fb="0" ids="40618">aminoguanidine</z:chebi> attenuated calcium-independent NOS activity in the <z:mpath ids='MPATH_124'>infarct</z:mpath> (P &lt; 0.05 vs. vehicle) without affecting calcium-dependent activity (P &gt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="40618">Aminoguanidine</z:chebi> did not affect resting cerebral blood flow or the cerebrovascular vasodilation elicited by <z:mp ids='MP_0002318'>hypercapnia</z:mp>, as determined by laser-Doppler flowmetry (n = 4) </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that <z:chebi fb="0" ids="40618">aminoguanidine</z:chebi> selectively inhibits iNOS activity in the area of infarction and reduces the volume of the <z:mpath ids='MPATH_124'>infarct</z:mpath> produced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>